An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist

Understanding the effects of bremelanotide on sexual response in women with sexual arousal disorder was critical for establishing its therapeutic viability. This early clinical study by Diamond, Earle, Heiman, and colleagues evaluated bremelanotide's (PT-141) effects on subjective sexual response in premenopausal women diagnosed with sexual arousal disorder.

The researchers administered bremelanotide to premenopausal women with sexual arousal disorder and assessed changes in subjective sexual response using validated measures of desire, arousal, and satisfaction. This clinical approach directly measured the outcomes most relevant to patients' quality of life.

The results demonstrated bremelanotide's positive effect on subjective sexual response, with treated women reporting meaningful improvements in sexual desire and arousal. These findings validated the melanocortin receptor-mediated mechanism as an effective pathway for addressing female sexual dysfunction.

This study was pivotal in establishing the clinical evidence that would eventually support bremelanotide's FDA approval. By demonstrating measurable improvements in sexual response through a novel peptide-based mechanism, the research opened a new therapeutic paradigm for women's sexual health that culminated in the first on-demand treatment for hypoactive sexual desire disorder.